Urotensin II receptor expression in prostate cancer patients: A new possible marker

ConclusionUrotensin II receptor is a potential marker of adverse pathological outcomes. Further studies should confirm our data and evaluate its role as a prognostic marker.

Source: The Prostate - November 8, 2018 Category: Urology & Nephrology Authors: Roberto Giulianelli, Stefano Nardoni, Dario Bruzzese, Cristina Falavolti, Gabriella Mirabile, Mariangela Bellangino, Giorgia Tema, Barbara Cristina Gentile, Luca Albanesi, Maurizio Buscarini, Paola Tariciotti, Riccardo Lombardo Tags: ORIGINAL ARTICLE Source Type: research